Access BNP & NT-proBNP Immunoassays

Featured News

Beckman Coulter Secures FDA Clearance for Heart Failure Assay on DxI 9000 Immunoassay Analyzer


Beckman Coulter, a global leader in clinical diagnostics, today announced U.S. Food and Drug Administration clearance of its Access NT-proBNP (N-terminal Pro B-type Natriuretic Peptide) assay for the assessment of heart failure in less than 11 minutes on the Beckman Coulter DxI 9000 Immunoassay Analyzer. 

Read more

News Releases

Learn more about the latest news and happenings at Beckman Coulter. 

See all news releases  

  • April 16, 2024 

    Beckman Coulters DxI 9000 Immunoassay Analyzer Extends Menu with New CE-Marked Hepatitis Assays at ESCMID Global

    Read more
  • March 12, 2024 

    Beckman Coulter and Fujirebio Expand Partnership to Develop Patient- friendly, Blood-based Neurodegenerative Disease Diagnostics

    Read more
  • February 6, 2024

    Beckman Coulter Appoints Kevin O'Reilly as New President

    Read more
  • May 7, 2024

    Beckman Coulter and MeMed Extend Partnership Advancing Host Immune Response Diagnostics

    Read more
Global Public Relations
Name Jeff Tarmy
Address Beckman Coulter World Headquarters
Brea California
Phone +1-617-467-7537

Stay Connected